主页 > 医学新闻 >
【drug-news】巴西拒绝美国Gilead公司抗艾药泰诺福
A health ministry spokesman said on Wednesday the patent request for the drug Tenofovir had been rejected, confirming a statement from the patent office announcing the decision on grounds that it lacked technological inventiveness.
The ministry said in April the drug, used by 31,300 patients in Brazil as part of the country's free treatment program, was "in the public interest." That was seen as an indication the patent request would be rejected.
Brazil may now import generic versions of the drug under a clause in World Trade Organization rules to sidestep drug patents in the name of public health.
No one at Gilead was immediately available for comment.
The medical group Doctors Without Borders said the decision could boost access to HIV/AIDS medicine in Brazil and throughout the developing world.
"Securing wider access to TDF (Tenofovir) is absolutely crucial," Tido von Schoen-Angerer of the group's Access Campaign, said in a statement.
"In the past, Brazil's production of ARV (antiretroviral) drugs has helped to bring down prices of ARVs globally. We hope this will happen again."
The group said an Indian-made generic version of Tenofovir approved by the World Health Organization cost $158 per person per year, compared to $1,387 charged by Gilead in Brazil.
After climbing in the 1990s, Brazil's HIV infection rate has steadied at around 0.5 percent and the number of new cases and deaths have been declining. Experts attribute the success to the government's promotion of condoms, free treatment, and the use of generic drugs.
In 2007, Brazil sidestepped a patent on Merck & Co Inc's AIDS drug Efavirenz to import a cheaper generic drug from India.
(Reporting by Stuart Grudgings; Editing by Todd Benson and Alan Elsner) 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 RIO DE JANEIRO (Reuters) Sept 04 - Brazil has rejected a patent request for an AIDS drug made by U.S. firm Gilead, opening the way for cheaper, generic versions to be used in the country's fight against the disease.
里约热内卢（路透社） 9月4日 巴西拒绝了美国吉利德公司一项抗艾滋病药物的制造专利申请，开创了一条更为廉价的用药途径，即在全国利用非专利药物来治疗艾滋病。
A health ministry spokesman said on Wednesday the patent request for the drug Tenofovir had been rejected, confirming a statement from the patent office announcing the decision on grounds that it lacked technological inventiveness.
卫生部门的发言人周三称，替诺福韦药物的专利申请已被驳回，这证实了专利局的声明，该声明宣布之所以做出这个决定是因为替诺福韦缺乏技术创新。
The ministry said in April the drug, used by 31,300 patients in Brazil as part of the country's free treatment program, was "in the public interest." That was seen as an indication the patent request would be rejected.
卫生部门表示，作为国家的部分免费治疗计划，也是出于公众的利益，四月份巴西已有31300名患者使用了该药物。这在外界看来其实已暗示拒绝了其专利申请。
Brazil may now import generic versions of the drug under a clause in World Trade Organization rules to sidestep drug patents in the name of public health.
巴西目前可能会在世界贸易组织的准则下，会以公众健康的名义进口非专利药物来规避专利药物。
No one at Gilead was immediately available for comment.
吉尔德公司没有对此事立即发表声明。
The medical group Doctors Without Borders said the decision could boost access to HIV/AIDS medicine in Brazil and throughout the developing world.
泛医药组织的各位博士称， 里约热内卢（路透社） 9月4日 巴西拒绝了美国吉利德公司一项抗艾滋病药物的制造专利申请，开创了一条更为廉价的用药途径，即在全国利用非专利药物来治疗艾滋病。
卫生部门的发言人周三称，替诺福韦药物的专利申请已被驳回，这证实了专利局的声明，该声明宣布之所以做出这个决定是因为替诺福韦缺乏技术创新。
卫生部门表示，作为国家的部分免费治疗计划，也是出于公众的利益，四月份巴西已有31300名患者使用了该药物。这在外界看来其实已暗示拒绝了其专利申请。
巴西目前可能会在世界贸易组织的准则下，会以公众健康的名义进口非专利药物来规避专利药物。
吉尔德公司并没有对此事立即发表声明。
泛医药组织的各位博士称，[标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-29 05:14
医学,生命科学网